AbCellera
- Company typePublic
- Founded2012
- HeadquartersVancouver, Canada
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
AbCellera firmographics
Firmographics- Name
- AbCellera
- Legal name
- AbCellera Biologics Inc.
- Website
- https://abcellera.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
AbCellera industry classification
Industry- Product category
- Biopharmaceutical Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where AbCellera is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
AbCellera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Partnership and Collaboration Revenue: AbCellera generates revenue through research collaborations with pharmaceutical and biotech partners, receiving upfront payments, research funding, milestone payments upon achievement of development milestones, and tiered royalties on net sales of approved products.
- Internal Pipeline Development: Company is transitioning from pure partnership model to developing proprietary drug candidates through clinical trials, with potential for future product revenue
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
AbCellera product offering
Product offeringCore offering
AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.
Product overview
AbCellera is a clinical-stage biotechnology company that operates an integrated antibody discovery and development platform. The core offering is a technology platform that combines microfluidics, single-cell screening, AI, and transgenic mouse technologies to discover therapeutic antibodies. The company is advancing an internal pipeline of antibody programs including ABCL635 (NK3R for menopausal vasomotor symptoms in Phase 2), ABCL575 (OX40L for atopic dermatitis in Phase 1), ABCL688 (autoimmunity, IND-enabling), and ABCL386 (oncology). The platform capabilities include T-cell engager technology for bispecific antibody development and GPCR/ion channel technologies for complex membrane protein targets. AbCellera also operates a 130,000 sq ft GMP clinical manufacturing facility in Vancouver. The company partners with pharmaceutical companies including Lilly, AbbVie, Jazz, and others for discovery programs while building its proprietary pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody Discovery Platform Integrated antibody discovery service combining proprietary microfluidic single-cell screening, AI-driven analysis, and transgenic mouse technologies to discover and generate therapeutic antibody candidates from natural immune responses, contracted by pharmaceutical and biotech partners.
- ABCL635 First-in-class antibody medicine targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause; first AbCellera-led program generated using GPCR and ion channel technologies, currently in Phase 1/2 clinical trials.
- ABCL575 Investigative monoclonal antibody targeting OX40L with a modified Fc domain for treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions; currently in Phase 1 clinical trial.
- ABCL688 Potential antibody medicine targeting a multipass complex membrane protein for treatment of an undisclosed indication in autoimmunity; second AbCellera-led program generated using GPCR and ion channel technologies, currently in IND-enabling studies.
- ABCL386 Potential antibody medicine for treatment of an undisclosed indication in oncology, part of AbCellera's internal proprietary pipeline.
- T-Cell Engager Platform Platform for designing and engineering T-cell engaging bispecific antibodies to address challenging tumor types by incorporating novel CD3, co-stimulatory (CD28, 4-1BB), and multispecific modalities for oncology and immunology applications; partnered with Jazz Pharmaceuticals, AbbVie, and others.
Quantifiable outcome
- 100+ antibody drug programs completed with 16 candidates reaching clinical stage
- +3 more outcomes
Companies that use AbCellera
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles1 record
AbCellera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
AbCellera partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major and core.
- Jazz PharmaceuticalsmajorPreclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. AbCellera receives $56M upfront for first two programs ($28M additional for third), with potential milestone payments up to $792M per program plus tiered royalties on net sales. Jazz receives exclusive worldwide development and commercialization rights.
- Eli LillycoreExpanded partnership from 2020 collaboration (which produced COVID-19 antibodies bamlanivimab and bebtelovimab) to discover therapeutic antibodies in immunology, cardiovascular disease, and neuroscience. Lilly gains development and commercialization rights while AbCellera receives upfront, milestone, and royalty payments.
- AbbViecoreExpanded collaboration to develop novel T-cell engagers for oncology, building on existing partnership relationship.
- RegeneroncorePartner for antibody drug discovery programs across various therapeutic areas.
- NovartiscorePartner for antibody drug discovery programs across various therapeutic areas.
- IncytecorePartner for antibody drug discovery programs across various therapeutic areas.
- BiogencorePartner for antibody drug discovery programs across various therapeutic areas.
- GileadcorePartner for antibody drug discovery programs across various therapeutic areas.
- Prelude TherapeuticscorePartner for antibody drug discovery programs across various therapeutic areas.
- EmpiricocorePartner leveraging AbCellera's technology for target discovery and validation with best-in-class antibodies to advance genetically validated targets into potential antibody-based therapies.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
AbCellera competitors and assessment
Company assessmentDirect peers
- Adimab: Adimab operates a leading yeast-based antibody discovery platform serving pharma and biotech partners through licensing and collaboration agreements. Direct comparable to AbCellera in the antibody discovery platform-as-a-service model, though using different core technology (yeast display vs. microfluidics).
- Absci: Absci is an AI-powered generative antibody discovery company combining high-throughput wet lab capabilities with deep learning models. Closely comparable to AbCellera in combining AI/ML-driven antibody design with proprietary wet-lab infrastructure for biologics discovery.
- Genmab: Genmab is a clinical and commercial-stage antibody therapeutics company with proprietary technology platforms (DuoBody, HexaBody, etc.) and a deep pipeline of partnered and proprietary antibody medicines. Comparable to AbCellera as a platform-driven antibody company generating revenue through partnerships and product royalties.
- argenx: argenx is a commercial-stage immunology-focused antibody therapeutics company with its own proprietary antibody discovery platform (SIMPLE Antibody) and a portfolio of approved products including VYVGART. Comparable to AbCellera's transition toward proprietary clinical pipeline, with overlapping focus on immunology indications.
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics for cancer and autoimmune disease, with proprietary DART and TRIDENT platforms for bispecific antibodies. Directly comparable to AbCellera's T-cell engager platform and clinical-stage antibody pipeline.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron is a large established biopharmaceutical company with its own proprietary VelociSuite antibody discovery technologies and a deep pipeline of approved antibody medicines. Functions as both an AbCellera partner and a competitor demonstrating how incumbents build internal antibody capabilities.
- Eli Lilly: Eli Lilly is one of AbCellera's largest pharma partners (COVID-19 antibodies, immunology, cardiovascular, neuroscience collaborations). As a global pharma major with growing in-house biologics capabilities, Lilly represents both the most significant partnership counterparty and a potential long-term competitive threat in antibody discovery.
Emerging players
- Generate Biomedicines: Generate Biomedicines is an emerging AI-driven generative biology company focused on designing novel protein therapeutics including antibodies using foundation models. Represents a next-generation competitor to AbCellera's AI-enabled antibody discovery approach with backing from Flagship Pioneering.
- Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science, including antibody and biologics design capabilities. Comparable to AbCellera's AI/ML-driven approach to therapeutic design, though broader in scope (small molecules plus biologics).
- Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology, automation, and machine learning to discover novel therapeutics. Comparable to AbCellera's data-driven approach to biologics discovery, though focused on small molecules and broader indication areas.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AbCellera social profiles
Digital presenceAbCellera financial estimates
Financial estimateRevenue estimate
Valuation estimate
AbCellera leadership team
Management profileNumber of profiles
Profiles10 records
AbCellera funding detail
Funding detailFunding overview
Funding rounds11 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AbCellera M&A and investment
M&A and investmentM&A4 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AbCellera
What does AbCellera do?
AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.
Is AbCellera a public or private company?
AbCellera is a public company. It is classified as public and is currently operating.
When was AbCellera founded?
AbCellera was founded in 2012. It employs 501 to 1,000 people.
Where is AbCellera based?
AbCellera is headquartered in Vancouver, Canada, in the North America region.
How does AbCellera make money?
Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are internal Pipeline Development.
Who are AbCellera's main competitors?
Direct peers on record are Adimab, Absci, Genmab, argenx and MacroGenics. Broad incumbents are Regeneron Pharmaceuticals and Eli Lilly. Emerging players are Generate Biomedicines, Schrödinger and Recursion Pharmaceuticals.
Does AbCellera have an API?
No public API is recorded for AbCellera.
What industry is AbCellera in?
AbCellera's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.